Annual Changes to the Nasdaq Biotechnology Index
NEW YORK, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq Biotechnology Index (Nasdaq: NBI), which will become effective prior to market open on Monday, December 20, 2021.
The Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (Nasdaq®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).
The following 129 securities will be added to the Index:
Exchange | Ticker | Company |
Nasdaq | BTX | Brooklyn ImmunoTherapeutics, Inc. |
Nasdaq | LXRX | Lexicon Pharmaceuticals, Inc. |
Nasdaq | CRIS | Curis, Inc. |
Nasdaq | HBIO | Harvard Bioscience, Inc. |
Nasdaq | EYPT | EyePoint Pharmaceuticals, Inc. |
Nasdaq | MTEM | Molecular Templates, Inc. |
Nasdaq | VIRX | Viracta Therapeutics, Inc. |
Nasdaq | AVXL | Anavex Life Sciences Corp. |
Nasdaq | INFI | Infinity Pharmaceuticals, Inc. |
Nasdaq | HROW | Harrow Health, Inc. |
Nasdaq | TNXP | Tonix Pharmaceuticals Holding Corp. |
Nasdaq | CMRX | Chimerix, Inc. |
Nasdaq | ADMA | ADMA Biologics Inc |
Nasdaq | SESN | Sesen Bio, Inc. |
Nasdaq | CLSD | Clearside Biomedical, Inc. |
Nasdaq | PRQR | ProQR Therapeutics N.V. |
Nasdaq | ALPN | Alpine Immune Sciences, Inc. |
Nasdaq | ACRS | Aclaris Therapeutics, Inc. |
Nasdaq | NVCR | NovoCure Limited |
Nasdaq | MRUS | Merus N.V. |
Nasdaq | OCX | Oncocyte Corporation |
Nasdaq | CRVS | Corvus Pharmaceuticals, Inc. |
Nasdaq | LPTX | Leap Therapeutics, Inc. |
Nasdaq | OBSV | ObsEva SA |
Nasdaq | MBIO | Mustang Bio, Inc. |
Nasdaq | OPTN | OptiNose, Inc. |
Nasdaq | SLDB | Solid Biosciences Inc. |
Nasdaq | NRXP | NRX Pharmaceuticals, Inc. |
Nasdaq | EOLS | Evolus, Inc. |
Nasdaq | COGT | Cogent Biosciences, Inc. |
Nasdaq | MREO | Mereo BioPharma Group plc |
Nasdaq | AQST | Aquestive Therapeutics, Inc. |
Nasdaq | EVLO | Evelo Biosciences, Inc. |
Nasdaq | VRCA | Verrica Pharmaceuticals Inc. |
Nasdaq | GRTS | Gritstone bio, Inc. |
Nasdaq | INBX | Inhibrx, Inc. |
Nasdaq | BCYC | Bicycle Therapeutics plc |
Nasdaq | CDAK | Codiak BioSciences, Inc. |
Nasdaq | MIRM | Mirum Pharmaceuticals, Inc. |
Nasdaq | IMPL | Impel NeuroPharma, Inc. |
Nasdaq | MORF | Morphic Holding, Inc. |
Nasdaq | OYST | Oyster Point Pharma, Inc. |
Nasdaq | ETNB | 89bio, Inc. |
Nasdaq | PHAT | Phathom Pharmaceuticals, Inc. |
Nasdaq | FDMT | 4D Molecular Therapeutics, Inc. |
Nasdaq | CVAC | CureVac N.V. |
Nasdaq | HRMY | Harmony Biosciences Holdings, Inc. |
Nasdaq | VTRS | Viatris Inc. |
Nasdaq | QSI | Quantum-Si Incorporated |
Nasdaq | PMVP | PMV Pharmaceuticals, Inc. |
Nasdaq | KYMR | Kymera Therapeutics, Inc. |
Nasdaq | NAUT | Nautilus Biotechnology, Inc. |
Nasdaq | DYN | Dyne Therapeutics, Inc. |
Nasdaq | CCCC | C4 Therapeutics, Inc. |
Nasdaq | HUMA | Humacyte, Inc. |
Nasdaq | ATHA | Athira Pharma, Inc. |
Nasdaq | LABP | Landos Biopharma, Inc. |
Nasdaq | TSHA | Taysha Gene Therapies, Inc. |
Nasdaq | ONCR | Oncorus, Inc. |
Nasdaq | PRAX | Praxis Precision Medicines, Inc. |
Nasdaq | CMPS | COMPASS Pathways Plc |
Nasdaq | PRLD | Prelude Therapeutics Incorporated |
Nasdaq | BOLT | Bolt Biotherapeutics, Inc. |
Nasdaq | ABCM | Abcam plc |
Nasdaq | STTK | Shattuck Labs, Inc. |
Nasdaq | KRON | Kronos Bio, Inc. |
Nasdaq | ALGS | Aligos Therapeutics, Inc. |
Nasdaq | AVIR | Atea Pharmaceuticals, Inc. |
Nasdaq | OLMA | Olema Pharmaceuticals, Inc. |
Nasdaq | SBTX | Silverback Therapeutics, Inc. |
Nasdaq | MRVI | Maravai LifeSciences Holdings, Inc. |
Nasdaq | BCAB | BioAtla, Inc. |
Nasdaq | GRCL | Gracell Biotechnologies Inc. |
Nasdaq | KNTE | Kinnate Biopharma Inc. |
Nasdaq | SEER | Seer, Inc. |
Nasdaq | ME | 23andMe Holding Co. |
Nasdaq | KMPH | KemPharm, Inc. |
Nasdaq | BVS | Bioventus Inc. |
Nasdaq | SNSE | Sensei Biotherapeutics, Inc. |
Nasdaq | SABS | SAB Biotherapeutics, Inc. |
Nasdaq | VOR | Vor Biopharma Inc. |
Nasdaq | ABCL | AbCellera Biologics Inc. |
Nasdaq | CGEM | Cullinan Oncology, Inc. |
Nasdaq | DBTX | Decibel Therapeutics, Inc. |
Nasdaq | CNTB | Connect Biopharma Holdings Limited |
Nasdaq | SANA | Sana Biotechnology, Inc. |
Nasdaq | ACHL | Achilles Therapeutics plc |
Nasdaq | IKNA | Ikena Oncology, Inc. |
Nasdaq | TERN | Terns Pharmaceuticals, Inc. |
Nasdaq | EWTX | Edgewise Therapeutics, Inc. |
Nasdaq | RXRX | Recursion Pharmaceuticals, Inc. |
Nasdaq | RXDX | Prometheus Biosciences, Inc. |
Nasdaq | TIL | Instil Bio, Inc. |
Nasdaq | DSGN | Design Therapeutics, Inc. |
Nasdaq | BMEA | Biomea Fusion, Inc. |
Nasdaq | RAIN | Rain Therapeutics Inc. |
Nasdaq | ATAI | ATAI Life Sciences N.V. |
Nasdaq | CADL | Candel Therapeutics, Inc. |
Nasdaq | HOWL | Werewolf Therapeutics, Inc. |
Nasdaq | TALS | Talaris Therapeutics, Inc. |
Nasdaq | CYT | Cyteir Therapeutics, Inc. |
Nasdaq | OMIC | Singular Genomics Systems, Inc. |
Nasdaq | DNAY | Codex DNA, Inc. |
Nasdaq | CNTA | Centessa Pharmaceuticals plc |
Nasdaq | IMGO | Imago BioSciences, Inc. |
Nasdaq | IPSC | Century Therapeutics, Inc. |
Nasdaq | SERA | Sera Prognostics, Inc. |
Nasdaq | RANI | Rani Therapeutics Holdings, Inc. |
Nasdaq | VERV | Verve Therapeutics, Inc. |
Nasdaq | DAWN | Day One Biopharmaceuticals, Inc. |
Nasdaq | JANX | Janux Therapeutics, Inc. |
Nasdaq | TKNO | Alpha Teknova, Inc. |
Nasdaq | GLUE | Monte Rosa Therapeutics, Inc. |
Nasdaq | RPID | Rapid Micro Biosystems, Inc. |
Nasdaq | AVTE | Aerovate Therapeutics, Inc. |
Nasdaq | ERAS | Erasca, Inc. |
Nasdaq | TNYA | Tenaya Therapeutics, Inc. |
Nasdaq | ICVX | Icosavax, Inc. |
Nasdaq | IMRX | Immuneering Corporation |
Nasdaq | RLYB | Rallybio Corporation |
Nasdaq | GRPH | Graphite Bio, Inc. |
Nasdaq | ABOS | Acumen Pharmaceuticals, Inc. |
Nasdaq | LYEL | Lyell Immunopharma, Inc. |
Nasdaq | ABSI | Absci Corporation |
Nasdaq | NUVL | Nuvalent, Inc. |
Nasdaq | OMGA | Omega Therapeutics, Inc. |
Nasdaq | CRBU | Caribou Biosciences, Inc. |
Nasdaq | MXCT | MaxCyte, Inc. |
Nasdaq | BLU | BELLUS Health Inc. |
As a result of the reconstitution, the following 21 securities will be removed from the Index:
Exchange | Ticker | Company |
Nasdaq | MNOV | MediciNova, Inc. |
Nasdaq | ASMB | Assembly Biosciences, Inc. |
Nasdaq | CNCE | Concert Pharmaceuticals, Inc. |
Nasdaq | ARDX | Ardelyx, Inc. |
Nasdaq | CALA | Calithera Biosciences, Inc. |
Nasdaq | XBIT | XBiotech Inc. |
Nasdaq | KALA | Kala Pharmaceuticals, Inc. |
Nasdaq | VYGR | Voyager Therapeutics, Inc. |
Nasdaq | ODT | Odonate Therapeutics, Inc. |
Nasdaq | VYNE | VYNE Therapeutics Inc. |
Nasdaq | UBX | Unity Biotechnology, Inc. |
Nasdaq | OSMT | Osmotica Pharmaceuticals plc |
Nasdaq | ORTX | Orchard Therapeutics plc |
Nasdaq | KLDO | Kaleido Biosciences, Inc. |
Nasdaq | BCEL | Atreca, Inc. |
Nasdaq | APRE | Aprea Therapeutics, Inc. |
Nasdaq | FUSN | Fusion Pharmaceuticals Inc. |
Nasdaq | INZY | Inozyme Pharma, Inc. |
Nasdaq | TSVTV | 2seventy bio, Inc. |
Nasdaq | ANIP | ANI Pharmaceuticals, Inc. |
Nasdaq | DRNA | Dicerna Pharmaceuticals, Inc. |
About Nasdaq
Nasdaq (Nasdaq: NDAQ) is a global technology company serving the capital markets and other industries. Our diverse offering of data, analytics, software, and services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on Twitter @Nasdaq, or at www.nasdaq.com.
Media Contact
Emily Pan
emily.pan@nasdaq.com
+1 (646) 637-3964
The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular financial product or an overall investment strategy. Neither The NASDAQ OMX Group, Inc. nor any of its affiliates makes any recommendation to buy or sell any financial product or any representation about the financial condition of any company or fund. Statements regarding Nasdaq’s proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.
- NDAQG -
